Traded Sep 3, 2026 · largest single transaction 17K
Show all 2 transactions
Sep 3, 202617K
DetailsOfficial recordSep 3, 20268,500
DetailsOfficial record
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
PLX · NYSE · Biological Products, (No Diagnostic Substances)
Protalix Biotherapeutics (PLX) · oqro.io/stocks/PLX · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
$2.90−0.16 (−5.23%)
Close of Nov 20, 2026, vs Nov 19 · end-of-day
Including 18 routine filings (option exercises, tax withholding, grants, gifts). Open-market trades only
Traded Sep 3, 2026 · largest single transaction 17K
Sep 3, 202617K
DetailsOfficial recordSep 3, 20268,500
DetailsOfficial recordTraded Sep 3, 2026 · largest single transaction 112K
Sep 3, 2026112K
DetailsOfficial recordTraded Sep 3, 2026 · largest single transaction 17K
Sep 3, 202617K
DetailsOfficial recordTraded Sep 3, 2026 · largest single transaction 17K
Sep 3, 202617K
DetailsOfficial recordTraded Sep 3, 2026 · largest single transaction 17K
Sep 3, 202617K
DetailsOfficial recordTraded Sep 3, 2026 · largest single transaction 320K
Sep 3, 2026320K
DetailsOfficial recordTraded Sep 3, 2026 · largest single transaction 17K
Sep 3, 202617K
DetailsOfficial recordTraded Sep 3, 2026 · largest single transaction 17K
Sep 3, 202617K
DetailsOfficial recordTraded Sep 3, 2026 · largest single transaction 17K
Sep 3, 202617K
DetailsOfficial recordInsider buying
First buy since 2023Traded Dec 19, 2025 · filed 4 days later
Since the trade +67.6% · S&P 500 +1.4% · to Nov 20
Bought 44% below the 52-week high, RSI 42, 11% under its 200-day average, 17 points behind the S&P 500 over 3 months
Insider selling
Traded Nov 18, 2025 · filed 1 day laterNot reported under a pre-arranged trading plan
Since the trade +54.3% · S&P 500 +4.5% · to Nov 20
A Protalix Biotherapeutics director sold $314 of Protalix Biotherapeutics shares. The filing does not indicate a pre-arranged trading plan.
Insider buying
Traded Jun 10, 2025 · filed 63 days later
Since the trade +83.5% · S&P 500 +14.4% · to Nov 20
A Protalix Biotherapeutics director paid $206K out of pocket for Protalix Biotherapeutics shares. Shares held went up 74% with this purchase.
0 open-market purchases and 0 open-market sales by insiders of PLX between Feb 16, 2026 and today, placed against the company's last 4 earnings releases. The latest on file was filed Nov 10, 2026. The data provider lists the next release for Mar 16, 2027; that date may change.
PurchaseSale30 days before a release30 days after
| Earnings release | 30 days before | On the day | 30 days after |
|---|---|---|---|
| Nov 10, 2026 | None | None | None |
| Aug 12, 2026 | None | None | None |
| May 13, 2026 | None | None | None |
| Mar 18, 2026 | None | None | None |
Companies set trading windows, which usually close shortly before results and reopen after them, and insiders may trade under 10b5-1 plans adopted months earlier. A date alone does not show what a person knew or why they traded. Past release dates are the dates the company filed its 8-K with Item 2.02. An upcoming date, when one is mentioned, comes from the data provider's earnings calendar (Finnhub): it is not a company filing, it is not estimated by OQRO, and it may change. Open-market purchases and sales as reported on Form 4. Largest purchases around earnings, all companies